239 related articles for article (PubMed ID: 35093670)
1. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
2. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
3. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
Cook N; Chen J; Zhou J; Wu D
Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
[TBL] [Abstract][Full Text] [Related]
4. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
[TBL] [Abstract][Full Text] [Related]
5. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
7. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
8. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
[TBL] [Abstract][Full Text] [Related]
9. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
10. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
11. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
Bao Q; Kumar A; Wu D; Zhou J
Drug Discov Today; 2024 Apr; 29(6):103986. PubMed ID: 38642703
[TBL] [Abstract][Full Text] [Related]
12. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes.
Cyrus S; Burkardt D; Weaver DD; Gibson WT
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824
[TBL] [Abstract][Full Text] [Related]
13. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
14. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
15. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
16. An overview of the development of EED inhibitors to disable the PRC2 function.
Liu KL; Zhu K; Zhang H
RSC Med Chem; 2022 Jan; 13(1):39-53. PubMed ID: 35224495
[TBL] [Abstract][Full Text] [Related]
17. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
18. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
J Virol; 2019 May; 93(9):. PubMed ID: 30814291
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.
Misawa K; Yamaotsu N; Hirono S
J Comput Aided Mol Des; 2021 May; 35(5):601-611. PubMed ID: 33635506
[TBL] [Abstract][Full Text] [Related]
20. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
